Literature DB >> 16361843

Salt--a potential 'uremic toxin'?

Eberhard Ritz1, Ralf Dikow, Christian Morath, Vedat Schwenger.   

Abstract

It has been known for decades that salt (NaCl) determines extracellular volume as well as blood pressure and is one cause of hypertension. The difficulty to control the NaCl balance and thus treat sodium overload and hypertension in patients on dialysis has been recognized by Scribner in the early days of dialysis. In recent years, an impressive body of evidence has accumulated indicating that in essential hypertension, NaCl--blood pressure independently--causes target organ damage such as left ventricular hypertrophy, microalbuminuria, and increased aortic stiffness. It has further been recognized that NaCl increases oxidative stress and, again blood pressure independently, amplifies tissue injury induced by aldosterone. In renal damage models, progression is dramatically accelerated by high NaCl intake. Sodium as a potential culprit in progression to target organ damage in terminal renal failure has not been well investigated so far. However, it is possible, and indeed likely, that sodium plays an adverse role in the genesis of target organ damage in terminal renal failure. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16361843     DOI: 10.1159/000089439

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  10 in total

Review 1.  Management of hypertension in chronic kidney disease.

Authors:  Pasquale Zamboli; Luca De Nicola; Roberto Minutolo; Valerio Bertino; Fausta Catapano; Giuseppe Conte
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

Review 2.  Endogenous digitalis: pathophysiologic roles and therapeutic applications.

Authors:  Alexei Y Bagrov; Joseph I Shapiro
Journal:  Nat Clin Pract Nephrol       Date:  2008-06-10

Review 3.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

4.  Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.

Authors:  Wakako Kawarazaki; Miki Nagase; Shigetaka Yoshida; Maki Takeuchi; Kenichi Ishizawa; Nobuhiro Ayuzawa; Kohei Ueda; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 10.121

5.  Endogenous ouabain and the renin-angiotensin-aldosterone system: distinct effects on Na handling and blood pressure in human hypertension.

Authors:  Paolo Manunta; John M Hamlyn; Marco Simonini; Elisabetta Messaggio; Chiara Lanzani; Maria Bracale; Giuseppe Argiolas; Nunzia Casamassima; Elena Brioni; Nicola Glorioso; Giuseppe Bianchi
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

6.  Sodium chloride promotes tissue inflammation via osmotic stimuli in subtotal-nephrectomized mice.

Authors:  Fumiko Sakata; Yasuhiko Ito; Masashi Mizuno; Akiho Sawai; Yasuhiro Suzuki; Takako Tomita; Mitsuhiro Tawada; Akio Tanaka; Akiyoshi Hirayama; Akihiro Sagara; Takashi Wada; Shoichi Maruyama; Tomoyoshi Soga; Seiichi Matsuo; Enyu Imai; Yoshifumi Takei
Journal:  Lab Invest       Date:  2017-02-06       Impact factor: 5.662

Review 7.  Aldosterone and glomerular podocyte injury.

Authors:  Miki Nagase; Toshiro Fujita
Journal:  Clin Exp Nephrol       Date:  2008-03-05       Impact factor: 2.801

8.  [Management strategy for hypertension in chronic hemodialysis: a model applied to patient education (FTE)].

Authors:  Ryme El Harraqui; Abda Naima; Bentata Yassamine; Intissar Haddiya
Journal:  Pan Afr Med J       Date:  2014-09-25

9.  Achieving salt restriction in chronic kidney disease.

Authors:  Emma J McMahon; Katrina L Campbell; David W Mudge; Judith D Bauer
Journal:  Int J Nephrol       Date:  2012-12-23

10.  The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial.

Authors:  Emma J McMahon; Judith D Bauer; Carmel M Hawley; Nicole M Isbel; Michael Stowasser; David W Johnson; Rachael E Hale; Katrina L Campbell
Journal:  BMC Nephrol       Date:  2012-10-19       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.